Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002335 · ClinicalTrials.gov registry record · Phase 1
The Safety and Effectiveness of 524W91
A Phase 1 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00002335: Completed Phase 1 study, sponsored by Glaxo Wellcome.
NCT00002335 is a Phase 1 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002335, a Phase 1 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
Interventions
- DRUG Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Phase | Phase 1 |
What the finished NCT00002335 record still lists
NCT00002335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Emtricitabine is the first listed.
NCT00002335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002335 about?
NCT00002335 is a clinical study titled "The Safety and Effectiveness of 524W91". To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
What is the current status of trial NCT00002335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants.
What interventions are being tested in trial NCT00002335?
The interventions under investigation include: Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00002335?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002335's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes